Oncomed Pharmaceuticals Inc (NASDAQ:OMED) Director Jack W. Lasersohn acquired 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were bought at an average cost of $3.55 per share, for a total transaction of $71,000.00. Following the purchase, the director now owns 151,095 shares of the company’s stock, valued at $536,387.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) traded down 3.83% during midday trading on Thursday, hitting $3.52. The stock had a trading volume of 1,727,859 shares. The stock’s market cap is $132.43 million. Oncomed Pharmaceuticals Inc has a 12-month low of $3.25 and a 12-month high of $15.35. The company’s 50-day moving average price is $4.47 and its 200 day moving average price is $7.63.

Oncomed Pharmaceuticals (NASDAQ:OMED) last announced its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.01. Oncomed Pharmaceuticals had a negative return on equity of 1,307.23% and a negative net margin of 409.54%. The company had revenue of $6.20 million during the quarter, compared to analysts’ expectations of $5.85 million. During the same quarter in the previous year, the firm earned ($0.90) earnings per share. The business’s quarterly revenue was down 2.4% compared to the same quarter last year. On average, equities research analysts predict that Oncomed Pharmaceuticals Inc will post ($1.77) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)

COPYRIGHT VIOLATION WARNING: “Oncomed Pharmaceuticals Inc (OMED) Director Acquires $71,000.00 in Stock” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/25/oncomed-pharmaceuticals-inc-omed-director-acquires-71000-00-in-stock.html.

Several hedge funds have recently made changes to their positions in OMED. BVF Inc. IL boosted its stake in shares of Oncomed Pharmaceuticals by 35.3% in the third quarter. BVF Inc. IL now owns 1,812,005 shares of the biopharmaceutical company’s stock worth $20,711,000 after buying an additional 472,669 shares in the last quarter. State Street Corp boosted its stake in shares of Oncomed Pharmaceuticals by 15.6% in the fourth quarter. State Street Corp now owns 341,271 shares of the biopharmaceutical company’s stock worth $2,628,000 after buying an additional 46,171 shares in the last quarter. FMR LLC boosted its stake in shares of Oncomed Pharmaceuticals by 10.1% in the fourth quarter. FMR LLC now owns 1,003,138 shares of the biopharmaceutical company’s stock worth $7,734,000 after buying an additional 91,835 shares in the last quarter. Disciplined Growth Investors Inc. MN boosted its stake in shares of Oncomed Pharmaceuticals by 8.6% in the fourth quarter. Disciplined Growth Investors Inc. MN now owns 326,900 shares of the biopharmaceutical company’s stock worth $2,520,000 after buying an additional 25,975 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Oncomed Pharmaceuticals by 86.5% in the fourth quarter. Renaissance Technologies LLC now owns 469,300 shares of the biopharmaceutical company’s stock worth $3,618,000 after buying an additional 217,700 shares in the last quarter. 42.24% of the stock is owned by institutional investors.

OMED has been the topic of a number of analyst reports. Zacks Investment Research lowered Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 target price on shares of Oncomed Pharmaceuticals in a research report on Saturday, March 11th. HC Wainwright set a $20.00 target price on Oncomed Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, March 11th. BMO Capital Markets reiterated a “buy” rating and set a $18.00 target price on shares of Oncomed Pharmaceuticals in a research report on Tuesday, March 14th. Finally, Leerink Swann increased their target price on Oncomed Pharmaceuticals from $6.00 to $10.00 and gave the stock a “market perform” rating in a research report on Tuesday, April 11th. Eight equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $12.11.

About Oncomed Pharmaceuticals

OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).

12 Month Chart for NASDAQ:OMED

Receive News & Ratings for Oncomed Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.